Tuesday 17 Nov 2026
main news image

KUALA LUMPUR (Nov 17): Duopharma Biotech Bhd (KL:DPHARMA) posted a 24% increase in net profit for the third quarter ended Sept 30, 2026 (3QFY2026), despite lower revenue.

Net profit rose to RM27.98 million from RM22.57 million a year earlier, while revenue fell 5.6% to RM210.05 million from RM222.49 million, according to a filing with Bursa Malaysia on Tuesday.

The pharmaceutical group’s stronger earnings were supported by a more favourable product mix, lower input costs and improved manufacturing and operational efficiencies, which helped cushion the impact of weaker sales. 

For the nine months ended Sept 30, 2026, cumulative net profit increased 29.5% to RM88.56 million from RM68.42 million a year earlier, although revenue declined 2.1% to RM692.29 million from RM707.01 million.

The lower revenue was mainly due to normalisation of public-sector insulin sales following exceptionally strong sales in the first half of FY2025. However, demand from the export and private market segments remained positive, alongside stronger contributions from its Ethical Specialty and Consumer Healthcare businesses. 

Duopharma said its improved profitability was driven by stronger gross profit margins, supported by a more favourable product mix and lower imported active pharmaceutical ingredient costs amid a strengthening ringgit. 

Lower stock write-offs, impairment losses and net finance costs also contributed to earnings growth, more than offsetting higher operating expenses.

The group did not declare any dividend for the quarter under review.

Looking ahead, Duopharma said it remains cautiously optimistic about delivering a satisfactory performance for FY2026, supported by its long-term supply contracts, product portfolio expansion and continued cost optimisation.

The group has secured three insulin supply contracts from the Ministry of Health worth a combined RM225.85 million, providing greater revenue visibility over the coming years.

It also secured extensions for the supply of 97 pharmaceutical and non-pharmaceutical products under the ministry's Approved Products Purchase List until June 30, 2027.

Duopharma said its recently announced five-year exclusive agreement with Enimmune Corporation for vaccine distribution would further strengthen its presence in preventive healthcare, subject to regulatory approvals.

Shares of Duopharma were down one sen at RM1.08 at Tuesday's noon break, valuing the group at about RM1.04 billion.

Edited ByIsabelle Francis
      Print
      Text Size
      Share